Seattle, WA -- (SBWIRE) -- 10/10/2019 -- Antiplatelet therapy is considered to be crucial in preventing aberrant platelet activation in pathophysiological conditions such as ischemia, myocardial infarction, and stroke. According to the Indian Journal of Pharm Science 2007 study, antiplatelet drugs reduce the incidence of cardiovascular events by 20-25% in people with established Coronary Artery Disease (CAD) or at high risk of CAD.
Manufactures in the antiplatelet drugs market focus on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation. Sustained development of new antiplatelet therapies is required as the risk for myocardial infarction and stroke, and death remain a persistent problem for individuals suffering from cardiovascular diseases.
Get Sample from Industry Experts @https://www.coherentmarketinsights.com/insight/request-sample/2190
Moreover, cost of drugs is also an important factor influencing compliance with treatment of disease and also constitutes an essential part of rational drug prescription. Pharmaceutical industry has several branded formulation of the same drug with large difference in selling price. For instance, in India, most of the drugs are available in brands and these drugs prescribed by clinician can adversely affect the patient's finance.
According to a study published in The International Journal of Basic & Clinical Pharmacology, 2016, the difference in the maximum and minimum price of the same drug manufactured by various pharmaceutical companies and percentage variation in cost per 10 tablets was calculated. Percentage variation in cost for oral antiplatelet drugs marketed in India was found to be- clopidogrel 150 mg tablet (148.7%), clopidogrel 75 mg (1067.3%), clopidogrel 300 mg tablet (42.9%), aspirin 75 mg (51.5%), aspirin 150 mg (69.8%), prasugrel 5 mg (94.4%), prasugrel 10 mg (54.8%), and ticlopidine 250 mg (32%). The lowest percent cost variation found is— ticagrelor 90 mg (0%).
Inquire about Discount on this Report @https://www.coherentmarketinsights.com/insight/request-discount/2190
Global Antiplatelet Drugs Market, By Drug Class:
Irreversible Cyclooxygenase (COX) Inhibitors
Adenosine Diphosphate (ADP) Receptor Inhibitors
Glycoprotein IIB/IIIA Inhibitors
Adenosine Reuptake Inhibitors
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market, By Mode of Administration:
Global Antiplatelet Drugs Market, By Application:
Percutaneous Coronary Interventions
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Otsuka Pharmaceutical Company, Ltd.
The Medicines Company
In combination therapy the highest price variation (235.6%) was found for aspirin (75 mg) and clopidogrel (75 mg) followed by aspirin (150 mg) and clopidogrel (75 mg) (24.2%). Therefore, there is a great need for the development of antiplatelet drug with low cost and less side effects along with great efficacy.
Browse the Full Report at https://www.coherentmarketinsights.com/market-insight/antiplatelet-drugs-market-2190
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.